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Neglected tropical diseases caused by kinetoplastid parasites (Trypanosoma brucei, 29 
Trypanosoma cruzi and Leishmania spp.) place a significant health and economic 30 
burden on developing nations worldwide. Current therapies are largely out-dated, 31 
inadequate and facing mounting drug resistance from the causative parasites. Thus, 32 
there is an urgent need for drug discovery and development. Target-led drug 33 
discovery approaches have focused on the identification of parasite enzymes 34 
catalysing essential biochemical processes, which significantly differ from equivalent 35 
proteins found in humans, thereby providing potentially exploitable therapeutic 36 
windows. One such target is ribose 5-phosphate isomerase B (RpiB), an enzyme 37 
involved in the non-oxidative branch of the pentose phosphate pathway, which 38 
catalyses the inter-conversion of D-ribose 5-phosphate and D-ribulose 5-phosphate. 39 
Although protozoan RpiB has been the focus of numerous targeted studies, 40 
compounds capable of selectively inhibiting this parasite enzyme have not been 41 
identified. Here, we present the results of a fragment library screening against 42 
Leishmania infantum RpiB, performed using thermal shift analysis. Hit fragments 43 
were shown to be effective inhibitors of LiRpiB in activity assays, and several were 44 
capable of selectively inhibiting parasite growth in vitro. These results support the 45 
identification of LiRpiB as a validated therapeutic target. The X-ray crystal structure 46 
of apo LiRpiB was also solved, permitting docking studies to assess how hit 47 
fragments might interact with LiRpiB to inhibit its activity. Overall, this work will guide 48 














The kinetoplastid protozoan parasites Trypanosoma brucei, Trypanosoma cruzi and 54 
Leishmania spp. are causative agents of the neglected tropical diseases (NTDs) 55 
human African trypanosomiasis (HAT), Chagas disease and leishmaniasis 56 
respectively. These NTDs continue to have a hugely damaging impact on global 57 
health and economies, yet currently available chemotherapeutic options are widely 58 
inadequate, and no effective human vaccines are available. Although significant 59 
progress has been made in recent years (1), particularly in the treatment of HAT (2), 60 
it has remained challenging to develop new drugs for leishmaniasis. Cutaneous 61 
leishmaniasis (CL) and visceral leishmaniasis (VL) pose a major health threat to an 62 
estimated 1 billion people, with over 1 million cases occurring annually, VL causing 63 
20,000-30,000 deaths (3, 4). Although a number of therapeutic candidates are 64 
progressing into clinical trials (5), most are at early stages and further leads are 65 
required to off-set the often high attrition rates of clinical development. This is 66 
particularly true in the case of leishmaniasis where treatment complexity is 67 
heightened by the requirements of different regions, which experience infections 68 
driven by different leishmanial species that also exhibit differing drug susceptibilities. 69 
Thus, sustained efforts to identify new avenues for anti-leishmanial lead discovery 70 
are vital. This need has led to extensive research into the metabolism of Leishmania 71 
spp. parasites, with a view to establishing areas of biochemical divergence from their 72 
hosts that can be exploited to combat them whilst minimising potential side-effects. 73 
 74 
The enzyme ribose-5-phosphate isomerase (Rpi) catalyses the isomerization of 75 
ribose-5-phosphate (R5P) to ribulose-5-phosphate (Ru5P) (Figure S1) in the non-76 
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oxidative branch of the pentose phosphate pathway (PPP) (Figure 1) (6, 7). 77 
Alongside glycolysis and the Kreb’s cycle, the PPP was one of the first identified 78 
metabolic pathways and is highly conserved in both prokaryotes and eukaryotes (8). 79 
The PPP supports key cellular functions, with the non-oxidative branch providing 80 
precursors for nucleotide, amino acid and vitamin biosynthesis, and the oxidative 81 
branch contributing to redox regulation (8). Though the oxidative branch of the 82 
pathway is confined to eukaryotes, the non-oxidative pathway is common to all 83 
organisms. Two physically and genetically distinct forms of Rpi are known to exist 84 
and were first characterised in Escherichia coli K12 (9), which produces both types. 85 
RpiA is present in all taxonomic groups but RpiB has only been found in bacteria and 86 
lower eukaryotes, including protozoa (10). 87 
The fact RpiBs are found exclusively in lower eukaryotes, including human 88 
pathogenic species, has led to them becoming the focus of numerous studies aiming 89 
to establish their essentiality, solving their protein structure and identifying specific 90 
inhibitors. Crystal structures for the RpiBs from E. coli and Mycobacterium 91 
tuberculosis have been determined to facilitate targeted drug design (11–13). 92 
Inhibition studies have centred on mimicking the structure of the high energy cis-93 
enediolate isomerisation reaction intermediate, such that inhibitors including 4-94 
phospho-D-erythronohydroxamic acid (4-PEH) have been identified (14). However, 95 
these inhibitors lack selectivity for RpiBs, given RpiAs also catalyse isomerisation via 96 
this high-energy intermediate, meaning they are unlikely to provide routes to the 97 
development of novel, selective therapeutics. 98 
The RpiBs from kinetoplastid parasites have also been examined. RpiB 99 
downregulation through RNA interference (RNAi) in T. brucei decreased parasite in 100 
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vitro growth and the infectivity of bloodstream forms towards mice (15). Mice infected 101 
with induced RNAi clones exhibited lower parasitaemia and a prolonged survival 102 
compared to control mice. Phenotypic reversion was achieved by complementing 103 
induced RNAi clones with an ectopic copy of the Trypanosoma cruzi gene (15). A 104 
crystal structure for T. cruzi RpiB (TcRpiB) has been determined (16), and research 105 
into the enzyme’s substrate specificity and potential inhibition has been conducted 106 
(17). Leishmania spp. RpiB has been studied in Leishmania donovani, Leishmania 107 
major and Leishmania infantum (10, 18, 19). In L. infantum null mutant generation 108 
was only possible when an episomal copy of the RpiB gene was provided, and the 109 
latter was preserved both in vitro and in vivo in the absence of drug pressure. This 110 
indicates the gene is essential for parasite survival (19). Although kinetoplastid 111 
RpiBs have also been shown to be susceptible to 4-PEH inhibition, no other specific 112 
inhibitors have yet been identified, potentially as studies of these enzymes have 113 
been largely dominated by structural modelling and in silico inhibition prediction (10, 114 
20). 115 
Here, we present the findings from a thermal shift (differential scanning fluorimetry) 116 
fragment library screening against recombinantly expressed L. infantum RpiB 117 
(LiRpiB). Hits obtained were analysed for their ability to inhibit LiRpiB via in vitro 118 
activity assay and for their anti-parasitic potency in cell viability assays. Results 119 
indicate that ability to interact with and effectively inhibit LiRpiB can be linked to anti-120 
parasitic efficacy, strengthening the case for LiRpiB as a validated drug target. We 121 
have also determined the first X-ray crystal structure for a Leishmania spp. RpiB, 122 
which permitted in silico docking analysis to speculate how the hit inhibitory 123 
fragments identified during this research might bind and inhibit LiRpiB activity. 124 
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Overall, this work provides novel insight that will inform the design of kinetoplastid 125 
RpiB-specific leads for drug development.  126 
Results  127 
LiRpiB recombinant protein was expressed, purified and subjected to thermal shift 128 
analysis. Thermal shift (differential scanning fluorimetry) is reliant on fluorescent 129 
dyes that signify when a protein has unfolded (21). One of the most commonly used 130 
fluorescent dyes is SYPRO® Orange (also used here), which forms non-specific 131 
interactions with hydrophobic protein residues (22). This means its signal will be 132 
strongest when the protein being analysed is unfolded and internal hydrophobic 133 
residues are exposed. By running an assay where reaction temperature is increased 134 
in degree increments per minute, it is possible to define the temperature at which a 135 
protein unfolds by monitoring its fluorescence. The temperature at which this occurs 136 
is designated the protein’s (Tm) or melting point (21). Compounds that significantly 137 
alter Tm may be potential inhibitors. Initial testing showed LiRpiB was amenable to 138 
SYPRO® Orange thermal shift analysis, with an average Tm of 59.6C being 139 
obtained for the protein. 140 
To permit screening of a fragment library, a positive control for ligand binding had to 141 
be established. The obvious choice was the enzyme’s substrate: ribose-5-phosphate 142 
(R5P). However, reported Km values for R5P against other RpiB enzymes were 143 
relatively high, with Stern et al. reporting a R5P Km of 4 mM against TcRpiB (17). 144 
Indeed, no significant shifts in LiRpiB Tm in the presence of 5-50 mM R5P could be 145 
obtained, supporting the suggestion that R5P has a relatively weak interaction with 146 
LiRpiB and other parasitic RpiBs. 147 
 148 
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It was hypothesised that 2-deoxyribose-5-phosphate (dR5P) may serve as an 149 
alternative, as it could be sufficiently similar to R5P to bind LiRpiB but also be 150 
retained in the enzyme’s active site for longer, prolonging the interaction. Testing a 151 
gradient of dR5P against LiRpiB (5-50 mM) resulted in significant shifts in LiRpiB Tm. 152 
To provide the consistency across replicates that would provide Z-factor values for 153 
each plate above the confidence threshold (Z-factor > 0.5), 30 mM was selected as 154 
the dR5P concentration for positive control reactions, reproducibly inducing a 6 °C 155 
shift in LiRpiB Tm (Figure 2). 156 
 157 
Approximately 800 fragments (Figure S2) across 11 fragment plates (Z-factors 158 
ranging from 0.5 – 0.8) (Figure S3), were screened at 1 mM effective concentration 159 
against LiRpiB. Graphs to summarise the data output for each fragment plate were 160 
compiled, with change in Tm relative to the negative control represented for each 161 
individual fragment (Figure S4).  162 
 163 
Upon reviewing the thermal shift data for the fragments, a threshold Tm shift of ± 5°C 164 
was set for fragment hit selection. This led to the selection of 15 fragment hits (Table 165 
1), which were followed up with enzymatic assays and anti-parasitic activity studies.  166 
 167 
Initially, fragment inhibition was tested in LiRpiB in vitro activity assays. Inhibition 168 
was compared to that achieved with the well-established Rpi inhibitor 4-PEH, which 169 
was tested at 10 mM concentration against both the forward (R5P -> Ru5P) and 170 
reverse (Ru5P -> R5P) isomerisation reactions (Table 2). Fragments 328 and 458 171 
were excluded from these assays due to solubility problems. To assess whether 172 
fragments could be tested in the forward reaction assay, their absorbance at 290 nm 173 
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(0.5 mM and 1 mM concentration) was measured. Almost all fragments displayed 174 
high absorbance values at 290 nm (OD ≥ 1) (Figure S5). Therefore, they could not 175 
be tested in the forward Rpi activity assay. 176 
Only fragments 2, 3, 25, 372, 540 and 576 were tested in this assay. Results for 177 
fragment 540 were also excluded during posterior analysis as, in the presence of 178 
R5P, the measured signal became saturated, which hindered a clear interpretation of 179 
the measurements obtained. Percentage inhibition values for LiRpiB that could be 180 
determined from the forward Rpi assay are shown (Table 2). No significant inhibition 181 
was found through this assay system except in the case of fragment 576: 1 mM 576 182 
inhibited the forward reaction to a similar extent as 10 mM 4-PEH (Figure 3). This 183 
suggests that 576 is (at least) as potent an inhibitor of LiRpiB as 4-PEH.  184 
 185 
The experimental limitations of the forward reaction assay do not apply to the 186 
reverse reaction assay. Therefore, all compounds could be tested in the reverse 187 
reaction assay system. Fragments 2, 338, 372 and 540 (1 mM) were capable of 188 
inhibiting the enzyme to a similar level as 10 mM 4-PEH (Table 2). Surprisingly, the 189 
inhibitory capacity of fragment 576 and 4-PEH were not as high in this assay system. 190 
This may be due to kinetoplastid RpiB activity favouring production of R5P, meaning 191 
higher levels of these inhibitors may be required in order to inhibit the enzyme in this 192 
direction. 193 
 194 
The 15 fragment hits and 4-PEH were also tested for their ability to inhibit L. 195 
infantum parasite growth at 100 µM concentration. Compounds were assayed 196 
against both L. infantum promastigotes (wild-type and LiRpiB sKO) and intra-197 
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macrophagic amastigotes (Table 2). As 4-PEH is only an inhibitor of LiRpiB at high 198 
millimolar range in protein activity assays (10 mM was routinely used to achieve 199 
inhibition during this study), it had been anticipated to show little to no anti-parasitic 200 
activity in vitro/in vivo (7), which was shown to be the case in treating with 100 µM. 201 
However, several of the fragment hits were shown to inhibit parasite growth at this 202 
concentration. Interestingly, fragments 152, 278 and 540 were seemingly less 203 
effective against the LiRpiB sKO promastigotes than the wild-type. Although sKO 204 
modifications against essential genes often do not produce significant phenotypic 205 
distinctions from wild-type parasites, it’s possible that compensatory up-regulation 206 
mechanisms accounting for the loss of a single LiRpiB allele are acting to protect the 207 
parasites from treatment with these compounds (to some extent). Conversely, 208 
fragment 576 was active against LiRpiB sKO promastigotes but was inactive against 209 
the wild-type. As the in vitro enzyme assay results point to fragment 576 being a 210 
more effective inhibitor of the LiRpiB forward reaction than the reverse reaction, this 211 
could indicate sKO parasites are rendered more susceptible to forward reaction 212 
inhibitors. The most active fragments against both L-infantum life-cycle forms were 213 
338 (Figure 4) and 540, which were also among the most potent inhibitors of the 214 
LiRpiB reverse reaction. Collectively, these data suggest that a possible mode of 215 
action for the observed anti-leishmanial activity of potent fragments, such as 338, is 216 
by modulating the activity of LiRpiB. 217 
 218 
To facilitate further development of inhibitor leads, a crystal structure for apo LiRpiB 219 
was determined at 1.6 Å resolution (Table 3). An LiRpiB functional dimer was 220 
established, and a LiRpiB tetramer could then be assembled from the monomer of 221 
 on M








the asymmetric unit via crystallographic symmetry (Figure 5). This is similar to the 222 
TcRpiB tetramer described by Stern et al (16). 223 
 224 
Each monomer of the dimer (hence also of the tetramer) is based on a Rossmann 225 
fold with a five-stranded parallel β-sheet flanked by three α-helices on one side and 226 
two on the other. A sixth α-helix (C-terminus) extends from the core domain to 227 
interact with the second subunit of the dimer. Each monomer subunit of the dimer 228 
forms one side of the active site cleft. Within the active site (Figure 6), key residues 229 
involved in substrate interaction that have been identified in RpiB homologues are 230 
conserved: Asp13, His14, Cys72, Thr74 and Arg116 from one subunit of the dimer 231 
and His105, Asn106, Arg140 and Arg144 from the other subunit of the dimer. This 232 
indicates the catalytic mechanism operated by the active site is consistent with other 233 
RpiBs. 234 
 235 
In comparison to the apo TcRpiB structure, a different orientation of Arg 116 (Arg113 236 
in TcRpiB) is observed (Figure 6). Also, Thr74 is present in LiRpiB in place of Ser71 237 
that occurs in TcRpiB, more in line with E. coli RpiB that also carries a Thr residue at 238 
this position (11, 16).  239 
 240 
Given the orientation of the sulfate ion in the active site, and the consequent 241 
suggestion that the R5P/Ru5P substrate will be oriented in a similar way (Figure 7A), 242 
this also indicates 4-PEH interaction with LiRpiB will be consistent with that 243 
established for other RpiBs (Figure 7B). Docking analysis predictions for anti-244 
parasitic fragment hits 338 and 540 indicates that the interaction of these fragments 245 
with the active site are likely to centre around residues His 14, Arg140, Arg144 246 
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(Figure 7C and 7D). Given these residues are conserved in RpiB active sites but not 247 
RpiAs, this could account for the selectivity of these fragments towards combatting 248 
parasites (Table 2). 249 
 250 
  251 
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Type B ribose-5-phosphate isomerase (RpiB) has been flagged as an attractive 253 
protein target for drug development to combat pathogens, given the critical role of 254 
this enzyme combined with its evolutionary divergence from mammalian RpiA. It has 255 
long been assumed it may be possible to design RpiB specific inhibitors yet, thus far, 256 
no such inhibitors have been identified.  257 
In this work, a fragment library screening was conducted for L. infantum RpiB, 258 
utilising thermal shift as the screening technique. Thermal shift assaying is 259 
commonly used to assess the potential of adding ligands to improve protein stability, 260 
aiding crystallization (21, 23, 24). Although not capable of identifying inhibitors 261 
directly, it has been widely used to facilitate this process (25–28), assisting in drug 262 
discovery efforts. The ability to apply this screening method to any amenable protein, 263 
regardless of function, makes thermal shift particularly valuable. This is perhaps 264 
most relevant when attempting to establish inhibitors for proteins that lack high-265 
throughput activity-based screening methods, as was the case for LiRpiB. Using this 266 
method, LiRpiB was screened against 851 different fragments. 15 hit fragments that 267 
produced ± 5 °C shifts in LiRpiB Tm were selected, progressing to LiRpiB activity 268 
assays and cell viability assays against L. infantum parasites. The activity assay 269 
results indicate that thermal shift screening was capable of identifying inhibitors as 270 
fragments 2, 338, 372, 540 and 576 showed LiRpiB inhibitory activity. Significantly, 271 
fragment hits 338 and 540 that inhibited LiRpiB in vitro also displayed anti-parasitic 272 
activity towards both L. infantum promastigotes (wild-type and LiRpiB sKO) and 273 
intramacrophagic amastigotes in an infection model, whilst also being well tolerated 274 
by mammalian THP1 cells in cytotoxicity assays. Overall, fragment 338 was 275 
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considered the best hit against LiRpiB given its superior potency. The fact that ability 276 
to interact with and inhibit LiRpiB was utilised to identify anti-parasitic hits 277 
strengthens the case for describing LiRpiB as a potential chemically validated drug 278 
target in Leishmania infantum. This is an important observation given the potential 279 
value of RpiB as a drug target in parasitic protozoa has formerly been deemed 280 
equivocal (6). Though not specifically examined in this study, the fact RpiB is highly 281 
conserved amongst Leishmania spp. makes it possible these findings could also 282 
apply to species beyond L. infantum.  283 
 284 
Previous research into RpiB has largely focused on understanding the enzyme’s 285 
reaction mechanism, particularly in comparison to RpiA, crystal structure elucidation 286 
and/or in silico docking studies. Notably, in the context of protozoan parasites, 287 
although the crystal structure established for T. cruzi RpiB has permitted 288 
computational ligand docking studies, potential hits have yet to have their anti-289 
parasitic properties confirmed (20). For many years, inhibition of Rpi has centred 290 
around the well-established inhibitor 4-PEH. However, low potency and lack of RpiB 291 
specificity render this compound inappropriate for chemotherapeutic applications. 292 
The inhibitory fragments reported here, several of which were markedly more potent 293 
than 4-PEH (1 mM fragment concentration was contrasted with 10 mM 4-PEH 294 
inhibitory activity), may be able to fill this void and provide initial scaffolds for 295 
structure-led rational optimisation of RpiB inhibitors. In the case of leishmania, the 296 
first crystal structures for a leishmanial RpiB, solved during this study, can greatly 297 
facilitate this process for L. infantum and other Leishmania spp..The structural 298 
resolution of LiRpiB indicates that, as might be anticipated from high levels of protein 299 
sequence homology, RpiB structure is highly conserved amongst protozoan 300 
 on M








parasites. Thus, there is potential for the design of inhibitors capable of inter-301 
kinetoplastid impact. Docking results for hit anti-parasitic fragments 540 and 338 302 
predict that their interaction with the active site of LiRpiB hinges on residues His 14, 303 
Arg 140 and Arg 144. These residues typically coordinate the phosphate moiety of 304 
substrate R5P, orienting and stabilising the substrate in the correct conformation for 305 
isomerisation. Thus, it’s possible fragments 540 and 338 compete with R5P in the 306 
binding of these key residues. Future co-crystallisation and/or structural modelling of 307 
the fragments (and, potentially, further analogues) with LiRpiB may shed further light 308 
on the RpiB catalytic mechanism but also, crucially, how to gain inhibitor specificity 309 
over RpiA. It will also be important to establish how the anti-parasitic fragment hits 310 
are turned over by the parasites, as currently speculations can only be made as to 311 
how intact fragment compounds could interact with LiRpiB.  312 
Furthermore, it is currently unknown whether any off-target effects are also 313 
contributing to fragment efficacy, which will be important to determine going forward, 314 
as well as anti-parasitic efficacy towards other Leishmania spp.. Overall, however, 315 
this work provides new avenues to pursue RpiB as a druggable target in Leishmania 316 
spp. and other pathogenic organisms. 317 
 318 
Material and Methods 319 
 320 
Cloning of the LiRpiB gene 321 
 322 
The LiRpiB gene was PCR amplified from L. infantum genomic DNA 323 
(MHOM/MA/67/ITMAP-263), using the following primers: 5’-324 
CAATTTCCATATGCCGAAGCGTGTTGC-3’ and 5’-325 
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CCCAAGCGAATTCTCTACTTTCCTTCC-3’. The purified LiRpiB PCR product was 326 
NdeI/EcoRI digested and cloned into a pGEM-T Easy vector (Promega). Presence of 327 
the LiRpiB open-reading frame (ORF) was confirmed via sequencing and was 328 
subsequently subcloned into a pET28a(+) expression vector (Novagen). 329 
Expression and purification of recombinant LiRpiB  330 
 331 
The pET28a(+) LiRpiB expression vector was transformed into E. coli BL21 (DE3) 332 
cells. The recombinant protein was expressed by induction of log-phase cultures in 333 
Luria-Bertani media (OD600 = 0.6) with 0.5 mM isopropyl-β-D-thiogalactopyranoside 334 
(IPTG) for 3 h at 37ºC with shaking at 250 rpm/ min. Bacteria were harvested 335 
through centrifugation (3077 g for 40 min at 4ºC) and suspended in 20 mL of buffer A 336 
(0.5 M NaCl, 20 mM Tris-HCl, pH 7.6). Samples were then sonicated using a 337 
Branson sonifier 250 under the following conditions: output 4, duty cycle 50%, 10 338 
cycles with 15 sec each. Samples were centrifuged (3077 g for 60 min at 4ºC) and 339 
the product supernatant was retained for further processing. Recombinant LiRpiB 340 
was purified in one step using Ni2+ resin (ProBond), pre-equilibrated in buffer A. The 341 
column was washed sequentially with 2-3 mL of the buffer A, 20 ml of the bacterial 342 
crude extract, 2 mL of buffer A 25 mM imidazole, 2 mL of buffer A 30 mM imidazole, 343 
2 x 2 mL of buffer A 40 mM imidazole, 2 mL of buffer A 50 mM imidazole, 10 mL of 344 
buffer A 100 mM imidazole, 5 mL of buffer A 500 mM imidazole and 8 ml of buffer B 345 
(1 M imidazole, 0.5 M NaCl, 200 mM Tris, pH 7.6). LiRpiB enzyme was eluted in the 346 
fractions of buffer A containing 100 or 500 mM of imidazole. Desalting was 347 
performed against 100 mM of Tris-HCl, pH 7.6 (storage buffer, reaction buffer for 348 
direct reaction), using PD-10 Desalting columns (GE Healthcare Code No 17-0851-349 
01).  350 
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Differential scanning fluorimetry with LiRpiB 352 
 353 
Differential scanning fluorimetry was set up in 96-well PCR plates employing a total 354 
reaction volume of 100 µL. Reactions consisted of 13 µM protein (LiRpiB) in 50 mM 355 
MOPs (pH 8.0) reaction buffer with 5 X SYPRO Orange dye (Invitrogen) as the 356 
fluorescent indicator of protein unfolding (Ex. 492 nm, Em. 610 nm). Fragments from 357 
an in-house library at the University of St Andrews, expanded from the Maybridge 358 
Rule of 3 (Ro3) library (25) were screened against RpiB at 1 mM concentration 359 
(0.5% DMSO final concentration per well). This library incorporates fragments that 360 
adhere to the chemical parameters ≤ 300 MW; ≤ 3.0 cLogP; ≤ 3 H-bond acceptors; ≤ 361 
3 H-bond donors; ≤ 3 rotatable bonds; ≤ 60 Å2 Polar Surface Area, properties which 362 
are predicted to increase the probability of viable fragment lead discovery (29), a 363 
more stringent application of the ‘Rule of 5’ criteria developed by Lipinski et al. to 364 
curate drug-like compound libraries (30). DMSO was used in negative control 365 
reactions and 30 mM deoxy-ribose-5-phosphate (dR5P) was added to positive 366 
control reactions. Each plate screened included 8-replicate negative and 8-replicate 367 
positive control reactions, to permit calculation of a Z-factor (31) (threshold = 0.5). 368 
Thermal shift scans were performed in a real-time PCR machine (Stratagene 369 
Mx3005P with software MxPro v 4.01) over a temperature range of 25°C to 95°C, 370 
ramping at 0.5°C min-1. Data were then exported to Excel for analysis using “DSF 371 
analysis”, modified from the template provided by Niesen et al (21). Melting point 372 
(Tm) values were calculated through non-linear regression analysis, fitting the 373 
Boltzmann equation to denaturation curves using GraphPad Prism as previously 374 
described (25). 375 
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Compound preparation for assays  377 
 378 
Compounds were dissolved in 100% DMSO at 100 mM, aliquoted and stored at -379 
20°C. The following procedure was applied for the solubilization of compounds in 380 
reaction buffer (100 mM Tris-HCl pH 7.6): 1 hour of vortex mixing, 15 minutes of 381 
ultrasound treatment and 1 hr of incubation at 37°C under strong agitation. The 382 
optical density (OD) at 290 nm of soluble compounds at 1 mM or 0.5 mM 383 
concentration was measured and only compounds with low absorbance values (OD 384 
< 1) were selected for analysis. The control compound 4-PEH was used as a 100 385 
mM stock in water and stored at -20ºC. 386 
 387 
LiRpiB activity assays 388 
 389 
Compounds were tested in the forward and/or reverse reaction at a final 390 
concentration of 1 mM. Concerning the forward reaction, a direct spectrophotometric 391 
method at 290 nm was used to quantify Ru5P formation in the presence of 12.5 mM 392 
R5P and 0.0025 mg/ml LiRpiB in a total volume of 300 µL (32). The reaction buffer 393 
was 100 mM of Tris-HCl pH 7.6. The absorbance was monitored at 37°C for 20 394 
minutes. The blank for each compound was assumed to be the absorbance at t=0. 395 
Compound inhibitory effect was quantified via measuring OD values in both the 396 
presence and absence of compound within the first 4 minutes of the assay and at the 397 
endpoint (t=20). The ratio between these values were used to determine compound 398 
percentage (%) inhibition. In the inverse reaction, a modification of Dische’s 399 
Cysteine-Carbazole method was used to quantify R5P formation (17). In a total 400 
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volume of 15 µL, 5 mM Ru5P, 0.0025 mg/mL LiRpiB and 5 µL of compound were 401 
incubated for 10 minutes at room temperature. Reaction buffer was 100 mM Tris-402 
HCl, 1 mM EDTA and 0.5 mM 2-mercaptoethanol, pH 8.4. For colour revelation, 15 403 
µL of 0.5% cysteinium chloride, 125 µL of 75% (v/v) sulfuric acid and 5 µl of a 0.1% 404 
solution of carbazole in ethanol were added to 10 µl of the previous mixture. The 405 
absorbance at 546 nm was determined following incubation for 30 minutes at room 406 
temperature in the dark. A blank without enzyme was always run in tandem with and 407 
without compound). The enzyme activity in the presence of compounds was 408 
measured by subtracting the OD values obtained in the presence of the enzyme to 409 
the blank values. Percentage inhibition was assessed via normalization of the activity 410 
values against those obtained in the compound negative control reactions. 411 
 412 
Parasite culture 413 
 414 
L. infantum (MHOM/MA/67/ITMAP-263) wild-type promastigotes and single knockout 415 
(sKO) LiRpiB promastigotes (19) were maintained at 27ºC in complete RPMI 416 
1640(33). Axenic amastigotes of the same strain expressing firefly luciferase (34) 417 
were grown at 37ºC with 5% CO2 in a cell-free medium (35).  418 
 419 
Growth inhibition assays 420 
 421 
The percentage growth inhibition, in promastigotes was performed by incubating the 422 
parasites in a 96-well plate with a starting inoculum of 1x106 cells/ml promastigotes 423 
during 72 hours with defined concentrations of the selected fragments. After 424 
incubation 50 µM of resazurin was added and incubated for 4 h. Fluorescence was 425 
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measured at 540 nm and 620 nm excitation and emission wavelength, respectively, 426 
using a Synergy 2 Multi-Mode Reader (Biotek). Activity against intracellular 427 
amastigotes was measured using THP1 cells infected with luciferase-expressing 428 
amastigotes as previously described (36). Fragments were screened at 100 µM in 429 
these assays. THP1 cytotoxicity was determined using an MTT assay following 430 
exposure of the THP1 cells to 100 µM of the fragments, as described elsewhere 431 
(37). 432 
 433 
Production and purification of LiRpiB for crystallization 434 
 435 
The purification protocol was based on that of TcRpiB (17). Briefly, full-length LiRpiB 436 
was produced as described above except that expression was induced overnight at 437 
18°C with 0.7 mM IPTG. Cells were harvested via centrifugation (2500 g for 30 min 438 
at 4ºC) and stored at -20°C until use. After thawing, bacterial pellets were suspended 439 
in lysis buffer (50 mM Tris.HCl pH 7.5, 300 mM NaCl, 1 mM DTT and 20 mM 440 
imidazole). Following sonication, the cell homogenate was centrifuged (56000 g for 441 
30 min at 4ºC) and the soluble tagged protein was purified by affinity 442 
chromatography on His60 Ni Superflow Resin (Clontech). Lysis buffer was used to 443 
wash the resin and protein was eluted with buffer A (50 mM Tris.HCl pH 7.5, 300 mM 444 
NaCl, 1 mM DTT and 500 mM imidazole). After removal of the His-tag (thrombin 445 
cleavage - overnight, 4°C), additional SEC was carried out on a HiLoad 16/60 446 
Superdex 200 equilibrated with buffer B (20 mM Tris.HCl pH 7.5, 150 mM NaCl, 2 447 
mM DTT and 1 mM EDTA). Fractions containing purified protein were pooled and 448 
protein was concentrated to ~12 mg/ml by ultrafiltration. 449 
 450 
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Crystallization and data collection 451 
 452 
Crystallization experiments were carried out using the sitting drop vapor diffusion 453 
method in 96-well plates using an Innovadyne nanodrop robot (300 nl protein 454 
solution + 300 nl crystallization condition). LiRpiB crystals grew at 277K in 100 mM 455 
HEPES (pH 7) and 2 M ammonium sulfate. Crystals were flash-frozen in liquid 456 
nitrogen in crystallization condition supplemented with 22% glycerol. Diffraction data 457 
were collected on beamline Proxima 1 (SOLEIL, Saclay, France) on a Pilatus 6M 458 
detector.  459 
 460 
Structure determination and refinement  461 
 462 
X-ray data were processed with XDS (38) and the software package CCP4 (39). The 463 
LiRpiB structure was solved by molecular replacement with Phaser (40, 41) using 464 
TcRpiB (Protein Data Bank entry code 3K7O) (16) as the search model. Model 465 
building and improvement were conducted by iterative cycles of manual building with 466 
Coot (42) and refinement with REFMAC (43). Structural data has been deposited in 467 
the Protein Data Bank under entry code 6FXW. 468 
 469 
In silico docking analysis 470 
 471 
Docking analysis was conducted using PyRx. Ligands (PEH and fragments 338 and 472 
540) were prepared using Chem3D, using the package’s MM2 structure optimisation 473 
tool. The LiRpiB functional dimer was prepared as a macromolecule for docking 474 
using AutoDock Tools (44, 45). PyRx docking analysis (46) was performed using a 475 
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grid box with dimensions x = 9.217; y = 9.292 and z = 11.459 to encompass the 476 
enzyme’s active site, determining the ligand conformations that would provide 477 
optimal binding energies (exhaustiveness = 16), which were then studied in relation 478 
to the LiRpiB active site structure using PyMOL. 479 
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Figure Legends 807 
 808 
Figure 1 – Overview of the pentose phosphate pathway (PPP). Both oxidative and 809 
non-oxidative branches of the pathway are depicted. Ribose-5-phosphate isomerase 810 
(Rpi) is highlighted in bold. G6PDH – glucose-6-phosphate dehydrogenase; 6-PGL; 811 
6-phosphogluconolactonase; 6-PGDH – 6-phosphogluconate dehydrogenase; RuPE 812 
– Ribulose 5-phosphate epimerase; TKT– transketolase; TAL – transaldolase. 813 
 814 
Figure 2: Confirmation LiRpiB is amenable to thermal shift library screening. 815 
Fluorescence profiles for 8 replicate LiRpiB negative control reactions (protein in the 816 
absence of any potential ligand) and 8 replicate positive control reactions (LiRpiB in 817 
the presence of 30 mM dR5P) are shown. LiRpiB Tm = 59.3  0.08 °C. The presence 818 
of 30 mM dR5P produced a 6 C Tm shift (LiRpiB Tm = 65.6  0.11 °C). 819 
 820 
Figure 3: Measurements of LiRpiB activity catalysing the forward reaction in the 821 
presence of the fragment 576. Values represent the enzyme activity with (squares) 822 
and without (circles) the fragment, and with 4-PEH (triangles). The reaction occurred 823 
in the presence of 12.5 mM R5P and 0.0025 mg/ml LiRpiB. Fragment 576 and 4-824 
PEH were tested at 1 mM and 10 mM respectively. The absorbance at 290 nm (OD) 825 
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was measured every 30 seconds during 20 minutes at 37℃. The values obtained 826 
with the compound 576 and in the control without the fragment correspond to the 827 
mean of duplicates. The values concerning the 4-PEH were obtained from a single 828 
enzymatic kinetic reading.  829 
Figure 4: Average dose response curves. EC50 and 95% confidence interval for 830 
miltefosine (A) and fragment 338 (B) anti-parasitic activity against wild-type (WT) and 831 
single knockout (sKO) RpiB promastigotes. The curves represent the merged output 832 
from the data of three independent curves. 833 
 834 
Figure 5: Reconstitution of LiRpiB structure. The green monomer represents the 835 
asymmetric unit and additional copies participating in tetramer formation through 836 
crystallographic symmetry are depicted in grey. 837 
 838 
Figure 6: LiRpiB active site occupied by a sulfate ion. Key residues for LiRpiB protein 839 
activity are labelled and depicted as sticks, water molecules as red spheres. 840 
Conformation of TcRpiB Arg113, as observed in the TcRpiB apo structure, is 841 
highlighted in brown transparent stick. 842 
 843 
Figure 7 – LiRpiB active site illustrating inhibitor substrate and inhibitor binding 844 
predictions. (A) R5P/Ru5P and (B) 4-PEH, predicted with reference to TcRpiB; (C) 845 
338 and (D) 540 fragment binding predictions from in silico docking analysis. The 846 
docking conformations depicted displayed optimal binding energy and highest level 847 
of intermolecular interactions. 848 
 849 
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Table 1: Fragment hits from thermal shift screening of LiRpiB. Fragment library 850 
number; name; chemical structure and observed Tm shift (C) for each fragment hit 851 
are provided. 852 
 853 
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Fragment ID Name Structure 
 




































































Table 2: Inhibitory capacity of compounds against LiRpiB  855 
The enzymatic inhibition of all the compounds was determined at 1 mM, except the 856 
4-PEH that was tested at 10 mM. The values correspond to the mean +/- SD of the 857 
inhibitory effect (%) relative to control (drug absence) from 2-3 independent assays 858 
performed in duplicate. The activity of 100 µM of each fragment against L. infantum 859 
promastigotes was determined using resazurin assay (72 hours). For the intra-860 
macrophagic parasites, THP1 cells infected with parasites expressing luciferase 861 
were used. The cytotoxicity and activity determinations were performed  with 100 µM 862 
of the fragments in a MTT assay involving PMA-differentiated THP-1 cells. Anti-863 
parasite and viability data represented is the average ± SD of at least two 864 
independent assays performed in at least triplicate. NA, not active; NT, not tested.  865 
Inhibitor LiRpiB inhibition 
(%) 
Anti-parasitic activity (%) THP1 
viability 
(%) 







2 10 ± 14 21 ± 2 N.A. N.A. 30 ± 8 92 ± 1 
3 12 ± 9 10 ± 4 14 ± 5 9 ± 0 79 ± 26 99 ± 3 
25 6 ± 1 6 ± 7 N.A. N.A. 40 ± 31 115 ± 26 
68 N.T. 19 ± 1 N.A. N.A. N.A. 120 ± 18 
152 N.T. 13 ± 8 31 ± 11 52 ± 24 N.A. 114 ± 15 
278 N.T. 4 ± 4 13 ± 1 28 ± 5 N.A. 19 ± 1 
338 N.T. 32 ± 10 100 ± 0 102 ± 2 100 ± 17 77 ± 14 
372 5 ± 15 26 ± 3 N.A. N.A. N.A. 96 ± 5 
383 N.T. -2 ± 1 N.A. N.A. N.A. 121 ± 16 
540 N.T. 23 ± 5 26 ± 15 64 ± 5 87 ± 15 71 ± 2 
565 N.T. 17 ± 1 N.A. N.A. N.A. 96 ± 0 
576 39 ± 22 14 ± 5 N.A. 69 ± 28 N.A. 21 ± 20 
626 N.T. -7 ± 8 N.A. N.A. N.A. 101 ± 4 
4PEH 51 ± 19 24 ± 4 N.A. N.A. N.A. 82 ± 1 
 866 
Table 3. Data collection and refinement statistics 867 
 LiRpiB/SO4 
Data collection  
 on M








Resolution (last shell) (Å) 19.75-1.57 (1.66-1.57) 
Space group F222 
Unit-cell parameters 
a, b, c (Å) 
     α, β, γ (°) 
 
a=80.87, b=83.55, c=89.35 
α=β=γ=90 
Completeness (last shell) (%) 99.6 (97.8) 
Redundancy (%) 6.5 
I/σ(I) (last shell) 23.20 (5.09) 
Rsym(I) (last shell) (%) 5.27(34.3) 
Refinement  
Protein molecule / A.U. 1 
Rwork (%) 14.5 
Rfree (%) 17.8 
r.m.s.d. in bond lengths (Å) 0.024 
r.m.s.d. in bond angles (°) 2.217 
Mean B factors (Å2) 17.35 
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